Elpek Kutlu G, Lacelle Chantale, Singh Narendra P, Yolcu Esma S, Shirwan Haval
Institute for Cellular Therapeutics and Department of Microbiology and Immunology, University of Louisville, Louisville, KY 40202, USA.
J Immunol. 2007 Jun 1;178(11):6840-8. doi: 10.4049/jimmunol.178.11.6840.
Tumors use a complex set of direct and indirect mechanisms to evade the immune system. Naturally arising CD4(+)CD25(+)FoxP3(+) T regulatory (Treg) cells have been implicated recently in tumor immune escape mechanism, but the relative contribution of these cells to overall tumor progression compared with other immune evasion mechanisms remains to be elucidated. Using the A20 B cell lymphoma as a transplantable tumor model, we demonstrate that this tumor employs multiple direct (expression of immunoinhibitory molecule PD-L1, IDO, and IL-10, and lack of expression of CD80 costimulatory molecule) and indirect (down-regulation of APC function and induction of Treg cells) immune evasion mechanisms. Importantly, Treg cells served as the dominant immune escape mechanism early in tumor progression because the physical elimination of these cells before tumor challenge resulted in tumor-free survival in 70% of mice, whereas their depletion in animals with established tumors had no therapeutic effect. Therefore, our data suggest that Treg cells may serve as an important therapeutic target for patients with early stages of cancer and that more vigorous combinatorial approaches simultaneously targeting multiple immune evasion as well as immunosurveillance mechanisms for the generation of a productive immune response against tumor may be required for effective immunotherapy in patients with advanced disease.
肿瘤利用一系列复杂的直接和间接机制来逃避免疫系统。天然产生的CD4(+)CD25(+)FoxP3(+)调节性T(Treg)细胞最近被认为参与了肿瘤免疫逃逸机制,但与其他免疫逃逸机制相比,这些细胞对肿瘤整体进展的相对贡献仍有待阐明。利用A20 B细胞淋巴瘤作为可移植肿瘤模型,我们证明该肿瘤采用了多种直接(免疫抑制分子PD-L1、IDO和IL-10的表达,以及共刺激分子CD80的缺乏表达)和间接(抗原呈递细胞功能下调和Treg细胞诱导)免疫逃逸机制。重要的是,Treg细胞在肿瘤进展早期作为主要的免疫逃逸机制,因为在肿瘤攻击前物理清除这些细胞导致70%的小鼠无瘤存活,而在已建立肿瘤的动物中耗尽这些细胞则没有治疗效果。因此,我们的数据表明,Treg细胞可能是癌症早期患者的重要治疗靶点,对于晚期疾病患者的有效免疫治疗,可能需要更有力的联合方法,同时针对多种免疫逃逸以及免疫监视机制,以产生针对肿瘤的有效免疫反应。